Thomas Steyer’s CRISPR Therapeutics CRSP Stock Holding History

Thomas Steyer’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-530,000	Closed	-$28.6M	–	168
2024 Q2	$28.6M	Buy	+530,000	New	+$30.7M	0.12%	66
2020 Q3	–	Sell	-150,000	Closed	-$11M	–	125
2020 Q2	$11M	Sell	150,000 -200,000	-57%	-$11.7M	0.09%	100
2020 Q1	$14.8M	Hold	350,000	–	–	0.13%	73
2019 Q4	$21.3M	Sell	350,000 -210,367	-38%	-$11.5M	0.14%	84
2019 Q3	$23M	Buy	560,367 +60,367	+12%	+$2.88M	0.17%	71
2019 Q2	$23.6M	Sell	500,000 -225,000	-31%	-$8.99M	0.15%	70
2019 Q1	$25.9M	Sell	725,000 -525,000	-42%	-$18.2M	0.19%	64
2018 Q4	$35.7M	Buy	1,250,000 +231,406	+23%	+$8.04M	0.26%	55
2018 Q3	$45.2M	Buy	1,018,594 +157,894	+18%	+$8.27M	0.27%	51
2018 Q2	$50.6M	Buy	860,700 +215,700	+33%	+$12.3M	0.31%	51
2018 Q1	$29.5M	Sell	645,000 -213,602	-25%	-$8.82M	0.2%	60
2017 Q4	$20.2M	Buy	+858,602	New	+$16.3M	0.16%	54

Other funds holding CRSP

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Thomas Steyer's CRSP Position: Q3 2024 in Review

Thomas Steyer sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 530,000 shares — an estimated $28.6M sold.

Thomas Steyer first reported a position in CRSP in Q4 2017 and held it in 12 quarters. The position peaked at $50.6M in Q2 2018. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

Thomas Steyer reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
Thomas Steyer sold 530,000 CRISPR Therapeutics shares in Q3 2024, an estimated $28.6M.
Thomas Steyer first reported a position in CRISPR Therapeutics in Q4 2017 and held it in 12 quarters.
Thomas Steyer's CRISPR Therapeutics position peaked at $50.6M in Q2 2018.
416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Farallon Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.